semaglutide vs tirzepatide weight loss side effects Semaglutide: Key Differences Explained Semaglutide vs Tirzepatide for Weight

The Food and Drug Administration (FDA) approved Wegovy for adults and children 12 years and older who have a body mass index (BMI) of 30 or higher or who have a BMI of 27 or higher with a related medical condition, such as high blood pressure, Type 2 diabetes, or high cholesterol

Retatrutide's developer, Eli Lilly, is expected to progress to Phase 3 trials, and regulatory submissions may follow in due course though no confirmed timeline for UK approval has been announced

And Novo Nordisk plans to initiate a global 68-week phase 3 trial in the second half of 2021 on the efficacy and safety of oral semaglutide 50 mg compared with placebo in 1000 people with obesity or overweight and comorbidities

Let me know!